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Abstract
Microenvironment-related immune and inflammatory markers, when combined with established Ki-67 and mor-
phology parameters, can improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms
(GEP-NENs). Therefore, we evaluate the prognostic value of microenvironment and tumor inflammatory features
(MoTIFs) in GEP-NENs. For this purpose, formalin-fixed paraffin-embedded tissue sections from 350 patients
were profiled by immunohistochemistry for immune, inflammatory, angiogenesis, proliferation, NEN-, and
fibroblast-related markers. A total of 314 patients were used to generate overall survival (OS) and disease-free
survival (DFS) MoTIFs prognostic indices (PIs). PIs and additional variables were assessed using Cox models to
generate nomograms for predicting 5-year OS and DFS. A total of 36 patients were used for external validation
of PIs and nomograms’ prognostic segregations. From our analysis, G1/G2 versus G3 GEP-NENs showed pheno-
typic divergence with immune-inflammatory markers. HLA, CD3, CD8, and PD-1/PD-L1 IHC expression separated
G3 into two sub-categories with high versus low adaptive immunity-related features. MoTIFs PI for OS based on
COX-2Tumor(T) > 4, PD-1Stromal(S) > 0, CD8S < 1, and HLA-IS < 1 was associated with worst survival (hazard ratio
[HR] 2.50; 95% confidence interval [CI], 2.12–2.96; p < 0.0001). MoTIFs PI for DFS was based on COX-2T > 4,
PD-1S > 4, HLA-IS < 1, HLA-IT < 2, HLA-DRS < 6 (HR 1.77; 95% CI, 1.58–1.99; p < 0.0001). Two nomograms
were developed including morphology (HR 4.83; 95% CI, 2.30–10.15; p < 0.001) and Ki-67 (HR 11.32; 95% CI,
5.28–24.24; p < 0.001) for OS, and morphology (PI = 0: HR 10.23; 95% CI, 5.67–18.47; PI = 5: HR 2.87; 95%
CI, 1.21–6.81; p < 0.001) and MoTIFs PI for DFS in well-differentiated GEP-NENs (HR 6.21; 95% CI,
2.52–13.31; p < 0.001). We conclude that G1/G2 to G3 transition is associated with immune-inflammatory pro-
file changes; in fact, MoTIFs combined with morphology and Ki-67 improve 5-year DFS prediction in GEP-NENs.
The immune context of a subset of G3 poorly differentiated tumors is consistent with activation of adaptive
immunity, suggesting a potential for responsiveness to immunotherapy targeting immune checkpoints.
Keywords: gastro-entero-pancreatic neuroendocrine neoplasm; microenvironment; immune and inflammatory markers; Ki-67; morphol-
ogy; disease-free survival
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Introduction
Gastro-entero-pancreatic neuroendocrine neoplasms
(GEP-NENs) are the most frequent neuroendocrine
tumors (NETs) [1]. The World Health Organization
(WHO) 2010 classification divides GEP-NENs into
G1, G2, and G3, according to Ki-67 and/or mitotic
index (MI) [2]. However, this classification was chal-
lenged by several studies showing its poor predictive
and prognostic power [3,4]. In 2017 WHO published a
new classification specific for pancreatic NENs, based
on proliferation parameters (Ki-67 and/or MI), and
morphological features (well-differentiated [WED] ver-
sus poorly differentiated [POD] tumors), and also on
percentage of neuroendocrine component (at least 30%
of the neoplasm) relative to the non-neuroendocrine
component [5]. Thanks to this classification, WED-
NENs can be further divided into NET G1 (Ki-
67 < 3%; MI <2/10 high-power fields [HPF]), NET G2
(Ki-67 3–20%; MI 2–20/10 HPF) and NET G3 (Ki-
67 > 20%; MI >20/10 HPF); on the other hand POD
tumors are classified as neuroendocrine carcinomas
(NECs) G3, having by definition Ki-67 > 20%. Further
studies [3,4], included in the European Neuroendocrine
Tumor Society (ENETS) 2017 Guidelines on POD-
GEP neoplasms [6], revealed that a 55% Ki-67 cut off
can discriminate POD-NENs with different median
overall survival (OS) and response to therapy. Indeed,
higher median OS in patients with Ki-67 ≤ 55% is
associated with lower responsiveness to platinum-based
therapy, which is conversely highly efficacious in
POD-NENs with Ki-67 > 55% [7].
Current GEP-NENs medical therapy includes
somatostatin analogues (SSAs), targeted therapies
(sunitinib and everolimus), peptide receptor radionu-
clide therapy and platinum-based chemotherapy. These
approaches aim directly at targeting tumor cells, thus
promoting disease chronicity rather than regression
[7]. On the other hand, immunotherapy targeting
immune checkpoints – which has shown efficacy in
several other cancer types – only targets nonneoplastic
elements of the tumor microenvironment, also known
as immune context [8], thus inducing immune-
mediated regression of the tumor mass. Several stud-
ies, conducted in other cancer types, have suggested
that patients responding to immunotherapy show abun-
dant PD-1+ T-cell infiltration that co-localizes with
PD-L1+ tumor or stromal cells [9]. In contrast, poor
response to immunotherapy is associated with modest
expression of PD-1/PD-L1 and high nuclear levels of
β-catenin [9]. Importantly, immunotherapy shows efficacy
in other GEP neoplasms, which share the same mutational
burden with GEP-NENs [8–11]. Conversely, microenvi-
ronment and tumor inflammatory features (MoTIFs) in
GEP-NENs have been poorly investigated to date
[12–14]. We carried out extensive GEP-NEN MoTIFs
profiling, testing their relationship with the WHO classes
and their potential prognostic relevance. Moreover, we
built two MoTIFs-based prognostic indices (PIs) for OS
and disease-free survival (DFS), and two nomograms
including selected MoTIFs and clinical parameters.
Materials and methods
Study setting and design
This study was performed according to the clinical
standards of the 1975 and 1983 Declaration of Hel-
sinki and was approved by the Ethical Committee of
Fondazione IRCCS Istituto Nazionale dei Tumori
(INT) (No. INT 21/16). A prospectively-maintained
institutional clinical database from 2 Northern Italy
(Milan) referral Centres for NET treatment (INT, and
Humanitas Research Hospital – HRH) was retrospec-
tively analyzed. The INT data were used to study the
MoTIFs, and to develop the MoTIFs PIs and nomo-
grams. The HRH series was used as an external vali-
dation set to assess the ability of the aforementioned
prognostic tools to discriminate patients’ prognosis.
Patients
Information on consecutive adult (≥18 years) patients
with NENs of any grade treated at INT and HRH from
1995 to 2015 with available tumor specimens (maxi-
mum 20 sections of 5 μm for each paraffin block) was
extracted from the database. Of note, in 1995 SSAs and
platinum-based treatment were established as standard
therapy for NENs: therefore, the choice has been made,
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taking into consideration that all the enrolled patients
underwent surgery, followed by SSAs treatment for
NETs G1–2, or chemotherapy for NETs G3 and NECs
G3. The neuroendocrine nature was histologically con-
firmed in all specimens by immunohistochemistry
(IHC) for chromogranin-A and synaptophysin.
IHC and MoTIFs scoring system
Biomarker expression was assessed by IHC in formalin-
fixed paraffin-embedded tumor tissue sections following
the manufacturer’s instructions (see supplementary
material, Table S1). The specificity of all reactions was
checked, replacing the primary antibody with a non-
related mouse immunoglobulin at comparable dilutions
or using normal serum alone. Positive and negative con-
trols were used as appropriate for each antibody, follow-
ing the manufacturer’s instructions. Sections were
stained with antibodies to immune (CD3, CD4, CD8,
PD-1, PD-L1, HLA-I, HLA-DR) and nonimmune
markers (COX-2, pS6, β-catenin, NGFR, α-SMA,
CD31). All these proteins were evaluated in both neo-
plastic cells and stromal cells. To minimize assessment
variability, IHC results for each protein (with the excep-
tion of β-catenin, α-SMA, CD31) were rendered semi-
quantitatively by adopting a scoring system taking into
account both staining marker extent (% positive cells)
and intensity. The expression (E) was defined as fol-
lows: up to 25% neoplastic cells, 1+; 26–50%, 2+;
51–75%, 3+; 76–100%, 4+. The immunostaining inten-
sity (I) was ranked as low (1+; fainter than internal con-
trols), normal (2+; as faint as controls), or strong (3+;
more intense than controls). E and I were combined into
a single score (S), calculated as E × I [15].
Statistical analysis
In the whole cohort of INT and HRH patients, the
expression of each of the MoTIFs in G1, G2 and G3
NEN subsets was compared by Kruskal–Wallis test
followed by Dunn’s multiple comparison test. The
binary association between all the investigated features
was investigated by Spearman’s correlation coefficient.
The study endpoints were OS and DFS and
univariable analyses were performed by estimating
Kaplan–Meier curves, with the log-rank test used to
compare subgroups, and by fitting Cox models. The
MoTIFs were modeled using a three-knot restricted cubic
spline [16]; nonsignificant nonlinear terms were omitted.
Details of the methods used to develop PIs and
nomograms are given in the supplementary material,
Supplementary materials and methods. In brief, based
on INT patients’ data we applied a methodology for
selecting and combining the MoTIFs to construct PIs
for OS and DFS [17]; each selected MoTIF was cate-
gorized into two prognostic categories, and that associ-
ated with the worst prognosis was given a score of 1;
the PI was the sum of the MoTIF scores. A backward
selection procedure was applied to select the variables
for inclusion in the multivariable Cox models used to
develop the nomograms. The initial set included the
end-point-specific MoTIF PIs and clinicopathological
variables chosen a priori: patients’ age, primary tumor
site, morphology (WED; POD), Ki-67 and β-catenin
(B0: absent; B1: cytoplasmic and/or membrane locali-
zation; B2: nuclear localization).
Results
Patients
Overall, 350 consecutively treated patients were included
in the study, 314 from INT (G1: n = 89 [28.3%]; G2:
n = 97 [30.9%]; G3: n = 128 [40.8%]) and 36 (all G3)
from HRH (Table 1). Median follow-up in the INT series
was 84 months (interquartile range [IQR], 42–133);
141 patients died and 283 had disease recurrence as first
event. All HRH patients died for the disease, and median
time to death was 11 (7–69) months.
IHC profiler of GEP-NENs microenvironment:
evolution in the immune- and inflammation-
related profile of tumor and stroma along with the
NET to NEC transition
Expression of immune, inflammatory and nonimmune
markers was evaluated in tumor (coded by superscript
Table 1. Demographic, clinical, and pathological characteristics of
the analyzed series
INT HRH
n = 314 n = 36
Age (years)
Median (first and third quartile) 59 (49–67) 61 (56–67)
Primary tumor site
Foregut 85 (27.1) 17 (47.2)
Midgut 178 (56.7) 12 (33.3)
Hindgut 51 (16.2) 7 (19.4)
Morphology
WED 210 (66.9) 3 (8.3)
POD 104 (33.1) 33 (91.7)
WHO grade
G1 89 (28.3) –
G2 97 (30.9) –
G3 128* (40.8) 36 (100)
*G3 includes 104 NEC and 24 NET.
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‘T’) and stromal (coded by superscript ‘S’) areas of
the lesions. In the whole cohort of 350 patients
(Figure 1 and see supplementary material, Figure S1).
The overall immune and inflammation-related profile
of the GEP-NENs showed highly significant changes
in the transition from G1/G2 to G3 tumors, as docu-
mented by comparison of NETs and NECs for expres-
sion of each of the investigated markers, with the
exception of COX-2s and of CD8s (see table at the
bottom of Figure 1). In detail, PD-L1T expression was
found only in a subset of G3 NEC and PD-L1S
increased in NECs compared to NETs. Overall PD-L1
expression (% of cases with either PD-L1S or PD-L1T
positivity at any level > 0) increased along the GEP-
NEN grading stages: from 8.99% in G1 and 12.37%
in G2 to 37.04% in G3 WED and 48.91% in G3 POD.
G3 NECs showed frequent loss of HLA-IT, increased
expression of CD31T,S and of α-SMAT,S and (in
89/164 tumors) a transition to ‘nuclear staining only’
in the β-catenin staining pattern (Figure 1 and see sup-
plementary material, Figure S1).
Testing all the binary associations among the inves-
tigated markers, across the three grading subsets, pro-
vided further insight into the widespread phenotypic
divergence between G1–2 NETs and G3 NETs and
G3 NECs (see supplementary material, Figure S2).
Collectively these results indicated that the transition
from G1/G2 NETs to G3 NETs and G3 NECs is asso-
ciated with profound changes in the tumor and stromal
profile for inflammatory and immune-related markers
and point to more frequent activation of adaptive
immunity in NECs (documented by increased CD3s,
PD-1s, and PD-L1s) counteracted by strong immune
escape mechanisms (HLA-IT loss), by expression of
PD-L1 on tumor or stroma, and by activation of
inflammatory pathways involved in negative regulation
of anti-tumor immunity (enhanced COX-2T and both
β-catenins/c-T and β-cateninn-T expression) (see supple-
mentary material, Figures S3 and S4).
Selected immune-related MoTIFs allow to build OS
and DFS PIs
The PIs were derived on the set of 314 INT patients.
Univariable Cox analysis (see supplementary material,
Table S2) showed significance of all MoTIFs but
pS6T. High values of CD3S, CD4S, PD-1S, PD-L1S,
COX-2T, and pS6T were associated with worse prog-
nosis (hazard ratio [HR] estimates >1); conversely,
high values of HLA-IT, CD8S, HLA-IS, HLA-DRS,
NGFRS, COX-2S, and pS6S were associated with good
prognosis (HRs <1). The OS PI included four selected
features, the positivity of which, associated with worse
survival, was defined as follows: COX-2T > 4, PD-
1S > 0, CD8S < 1, and HLA-IS < 1. Figure 2 (left)
shows the OS curves according to the PI. Using
univariable Cox analysis the HR corresponding to a
unit increment of the PI was 2.50 [95% confidence
interval (CI), 2.12–2.96; Wald test p < 0.0001; the
Harrell C statistic (C) (95% CI) = 0.761 (0.726–0.769)
(optimism-adjusted C = 0.761).
Even for DFS the PI methodology selected COX-2T
and PD-1S, together with other three immune features,
HLA-IS, HLA-IT, and HLA-DRS. Positivity was
defined as follows: COX-2T > 4, PD-1S > 4, HLA-
IS < 1, HLA-IT < 2, HLA-DRS < 6. Figure 2 (right)
shows the Kaplan–Meier DFS curves according to the
PI. The Cox model HR corresponding to a unit incre-
ment of the PI was 1.77 (95% CI, 1.58–1.99; Wald
test p < 0.0001; C = 0.668 [0.637–0.699] [optimism-
adjusted C = 0.668]).
PIs composition according to the selected variables
is represented in terms of scores in supplementary
material, Tables S3 and S4, and in supplementary
material, Figure S5 in terms of original semi-
quantitative values. In the HRH series we were able to
verify the prognostic segregation operated by the
MoTIFs PIs (see supplementary material, Supplemen-
tary materials and methods and supplementary mate-
rial, Figure S6). These results suggest that increasing
inflammation (tumor COX-2), loss/downmodulation of
HLA Class I molecules (even when expressed on stro-
mal cells) and enhanced T cell functional impairment
(PD-1) have a significant and negative impact on both
OS and DFS.
Morphology and Ki-67 have their main prognostic
impact on OS, while DFS is associated with
morphology and selected immune-related MoTIFs
OS and DFS curves according to grade or morphology
are shown in supplementary material, Figure S7. Mor-
phology segregated two groups with very divergent
OS and DFS, with worse prognosis associated with
POD tumors. However, G1-2 (Ki-67 ≤ 20%) patients
shared similar OS. For this reason, in the following
analyses, we evaluated Ki-67 as a continuous variable
in order to exploit its informative content. By
univariable Cox analysis (see supplementary material,
Table S4), morphology and Ki-67 showed stronger
association (higher HR estimates) than the MoTIF var-
iables with both OS and DFS; they were selected by
the backward procedure and were included in the Cox
model used to generate the OS nomogram (Table 2).
We explored whether the prognostic effect of one vari-
able could vary at different levels of the other, but no
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Figure 1. MoTIFs profile of 350 GEP-NENs classified according to WHO grading, Ki-67 score and morphology. Results of semi-quantitative
analysis (IHC scores) for expression of the indicated markers in each lesion is represented by the color code shown on the right-hand side of
the figure. Expression of each marker was evaluated in the tumor (superscript T) or in the stroma (superscript S). The β-cateninT IHC score
reflects surface or cytoplasmic (s/c) staining. To aid the interpretation of data, within each subset defined by WHO grading, the tumor samples
were ranked according to the sum of IHC score values of the immune-related markers (HLA-IT, PD-L1T, CD3S, CD4S, CD8S, PD-1S, PD-L1S, HLA-
IS, HLA-DRS). Therefore, lesions with the highest sum of these IHC scores are at the top of each grading subset. Ki-67 score for each lesion was
color coded as indicated in the legend on the right-hand side of the figure. For each lesion a graph is shown indicating length of patient sur-
vival (years) and related death/censoring information (*Black: DOD; white: censored). Table at the bottom of the figure: expression of each
marker was compared in the three main WHO grading subsets by Kruskal–Wallis test followed by Dunn’s multiple comparison test. Up arrows
and down arrows indicate increase or decrease of expression, respectively, in the subset with higher grading compared to the subset with lower
grading. Number of arrows (1, 2, or 3) for each comparison reflects increasing significance (p < 0.05, p < 0.01, or p < 0.001, respectively).
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significant results were obtained (p for interac-
tion = 0.222). The nomogram allows 5-year OS pre-
diction according to specific morphology and Ki-67
values, and it is useful for exploiting the information
given by Ki-67 as a continuous variable (Figure 3, and
supplementary material, Figure S8 for nomogram-
predicted OS in WED and POD subsets). Based on the
above results, we also derived an OS stratification of
G3 patients into three groups (see supplementary
material, Figure S9): better prognosis, Ki-67 ≤ 55%,
WED; intermediate prognosis, Ki-67 ≤ 55%, POD;
worse prognosis, Ki-67 > 55%, POD.
In the multivariable DFS Cox model, the backward
procedure selected morphology and MoTIFs PI
(including COX-2T, PD-1S, HLA-IS, HLA-IT, and
HLA-DRS). The interaction between the two variables
was not statistically significant, but achieved a P value
as low as 0.050, disclosing a different prognostic effect
of morphology at different levels of PI or vice versa: at
increasing PI the importance of morphology decreased
(Table 2, HR = 10.23 for PI = 0 versus HR = 2.87 for
PI = 5). Conversely, the PI was more able to segregate
WED (HR = 6.21) than POD patients’ prognosis
(HR = 1.74). Thus, we decided to retain such interac-
tion in the final Cox model used to generate the DFS
nomogram (Table 2 and Figure 4). The interaction
effect is clearer in the nomogram (Figure 4); the mor-
phology effect is represented by the length of the axis
(the longer the greater), and is greater at low PI levels
(the longest axis corresponds to PI = 0) and decreases
at increasing PI (the shortest axis corresponds to PI = 5).
The nomogram calibration plots are shown in
supplementary material, Figure S10; the nomogram
discriminative ability was very good for OS (C = 0.860
[0.838–0.882]; optimism-adjusted C = 0.860), and was
slightly lower for DFS (C = 0.732 [0.705–0.758];
optimism-adjusted C = 0.731). In the HRH series we
were able to verify the prognostic segregation operated
by the nomograms (see supplementary material, Sup-
plementary materials and methods and supplementary
material, Figure S11).
Taken together these results suggest that DFS may
be improved by preexisting immunity (which
explains the impact of immune-related MoTIFs on
Figure 2. Kaplan–Meier curves for OS (left) and DFS (right) according to the PIs based on MoTIFs in the INT series. The MoTIFs PI for OS
assumed values from 0 to 4, and the MoTIFs PI for DFS assumed values from 0 to 5.
Table 2. Results of the multivariable Cox models for OS and DFS
used to derive the nomograms
HR 95% CI P value
OS model
Ki-67* <0.001
70.0% versus 1.8% 11.32 (5.28–24.24)
Morphology <0.001
POD versus WED 4.83 (2.30–10.15)
DFS model
Morphology <0.001†
POD versus WED with MoTIFs
PI = 0
10.23 (5.67–18.47)
POD versus WED with MoTIFs
PI = 5
2.87 (1.21–6.81)
MoTIF PI <0.001†
5 versus 0 with morphology
WED
6.21 (2.52–13.31)
5 versus 0 with morphology
POD
1.74 (0.70–4.30)
*Fitted through 3-knots restricted cubic spline; the two values are, respec-
tively, the third and first quartile of Ki-67 distribution.
†Wald test P value of the main effect and interaction between morphology
and MoTIF PI.
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the DFS model). On the other hand, OS appears to be
mainly associated with tumor-intrinsic biological
aggressiveness (marked by POD morphology and
high Ki-67), features that can no longer be
counteracted even by a preexisting spontaneous
immune response.
Discussion
The quest for developing an improved classification of
GEP-NEN, and specifically of the POD NEC G3 sub-
set, stems from two distinct but overlapping needs,
related to prognosis and treatment. On one hand, as
Figure 3. Nomogram to predict 5-year OS. The nomogram was derived from a multivariable Cox model including the two selected vari-
ables, morphology and Ki-67. Instructions: the nomogram provides a method of calculating 5-year OS probability on the basis of a
patient’s combination of covariates. Locate the tumor Ki-67 value, draw a line straight upwards to the Points axis to determine the score
associated with Ki-67. Do the same for morphology, sum the two scores and locate the total score on the total points axis. Draw a line
straight downwards to the 5-year OS axis to obtain the probability.
Figure 4. Nomogram to predict 5-year DFS. The nomogram was derived from a multivariable Cox model including the two selected vari-
ables, morphology and MoTIFs PI, together with their interaction. Instructions: the nomogram provides a method of calculating 5-year
DFS probability on the basis of a patient’s combination of covariates. Locate the axis corresponding to morphology and MoTIFs PI value
and draw a line straight upwards to the points axis corresponding to that combination. Draw a line straight downwards to the 5-year
DFS axis to obtain the probability.
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outlined in the recent ENETS consensus guidelines
[6], the available evidence suggests that POD NENs
(NECs G3) are a heterogenous set of tumors, whose
complexity and prognosis are not fully dissected by
the available classification parameters (Ki-67 and mor-
phology). On the other hand, advanced NENs remain
poorly responsive to conventional (chemotherapy) or
targeted approaches. Thus, there is an urgent need to
identify new biological or molecular markers defining
previously undetected subsets of advanced NEN
patients who may be potentially responsive to innova-
tive treatments such as immunotherapy [18].
In this study we found that the immune-related
profile of GEP-NENs shows a clear shift at the
G1/G2–G3 transition (both NETs and NECs). This
grading-related evolution of the GEP-NEN immune
profile suggested promotion of adaptive immunity in a
subset of G3 NEC being counteracted by immune
escape mechanisms (HLA-IT loss) and by promotion
of inflammatory mechanisms that negatively regulate
adaptive immunity (COX-2T and β-cateninT). Tumor
and microenvironment immune profiling in the G3
subset allowed the identification of two groups:
patients with reduced expression of HLA-IT, associ-
ated with reduction of lymphoid markers, CD3S and
CD8S and loss of PD-L1S (these patients have the
worst prognosis and appear less suitable for immuno-
therapy (see supplementary material, Figure S3). On
the other hand, patients with retention of expression of
HLA-IT and the presence of a lymphoid infiltrate
(CD3S, CD8S, PD-L1S) have a more favorable progno-
sis and could potentially be responsive to immunother-
apy (see supplementary material, Figure S3) [18,19].
A weak but significant inverse correlation was
found between Ki-67 and HLA-IT (r = −0.180) and
between Ki-67 and CD8S (r = −0.293), while PD-L1T
and Ki-67 showed a direct correlation (r = 0.280).
These findings suggest that increased tumor grading
(captured by Ki-67) is associated also with impairment
of anti-tumor immunity through HLA-I down-
modulation, reduced CD8 infiltration and enhanced
PD-L1 expression on tumor cells. We also studied
MoTIFs prognostic value and generated OS and DFS
PIs based on selected MoTIFs able to stratify patients’
prognosis. The negative impact on DFS of COX-2T
and PD-1S and the positive impact of HLA-IS, HLA-
IT, and HLA-DRS have a potentially straightforward
interpretation: COX-2T has been shown to mediate
inhibition of type-I interferon (IFN) and T cell-
mediated anti-tumor responses [20], while a high
expression of PD-1 can mark functionally impaired
(exhausted) T cells at tumor sites [21]. In contrast,
retained HLA- Class I and Class-II expression in the
tumor microenvironment are essential requisites for
tumor-antigen recognition by CD8+ and CD4+ T cells
[22,23]. Therefore, the specific MoTIFs selected by
the DFS model strongly point to the relevance of a
functional adaptive immune response in delaying
tumor relapse.
Finally, two nomograms were elaborated based on
MoTIFs and WHO prognostic parameters for estimat-
ing 5-year OS and DFS probability. The nomogram
findings showed that the combination of morphology
and Ki-67 is the best prognosticator of OS in NENs.
Moreover, the association of POD morphology and a
Ki-67 threshold of 55% enables the identification of
three G3 subpopulations with different OS, in line
with previous studies [3,4]. The analysis of tumor
microenvironment showed that no biomarker was rele-
vant enough to modify the prognostic value of the
WHO 2017 classification [5]. Anyway, these results
suggest that DFS may be improved by preexisting
immunity, which explains the impact of immune-
related MoTIFs on the DFS model, while OS appears
to be mainly associated with tumor-intrinsic biological
aggressiveness (marked by POD morphology and high
Ki-67), features that can no longer be counteracted
even by a preexisting spontaneous immune response.
This study has some limitations. First, the HRH
series only included G3 (both NETs and NECs)
patients, thus the external validity of our tools should
be demonstrated on G1-2 patients. Second, although
we showed different levels of MoTIFs association
according to grade, in the absence of a large G3 popu-
lation we could not generate G3-specific prognostic
tools.
In conclusion, this study shows that microenvironment-
related immune and inflammatory markers can improve
prognostic prediction in GEP-NENs, when combined with
established Ki-67 and morphology parameters. Moreover,
at least a subset of G3 POD (NECs) has microenviron-
ment features consistent with spontaneous activation of
adaptive immunity (co-expression of CD3, CD4, CD8,
PD-1, and PD-L1), suggesting potential for responsive-
ness to immunotherapy targeting immune checkpoints.
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